Wieder HA[au] - Search Results

Year	Number of Results
2004	1
2005	1
2006	2
2007	6
2008	2
2009	1
2010	1
2011	4
2013	1
2014	2
2024	0

1

PET tracers in musculoskeletal disease beyond FDG.

Wieder HA, Pomykala KL, Benz MR, Buck AK, Herrmann K. Wieder HA, et al. Semin Musculoskelet Radiol. 2014 Apr;18(2):123-32. doi: 10.1055/s-0034-1371015. Epub 2014 Apr 8. Semin Musculoskelet Radiol. 2014. PMID: 24715445 Review.

2

Clinical use of bone-targeting radiopharmaceuticals with focus on alpha-emitters.

Wieder HA, Lassmann M, Allen-Auerbach MS, Czernin J, Herrmann K. Wieder HA, et al. World J Radiol. 2014 Jul 28;6(7):480-5. doi: 10.4329/wjr.v6.i7.480. World J Radiol. 2014. PMID: 25071888 Free PMC article. Review.

3

[18F-FDG-PET in therapy response of esophageal cancer].

Wieder HA, Herrmann K, Ott K, Krause BJ. Wieder HA, et al. Radiologe. 2007 Feb;47(2):110-4. doi: 10.1007/s00117-006-1461-9. Radiologe. 2007. PMID: 17225182 Review. German.

4

Esophageal cancer.

Wieder HA, Stahl A, Lordick F, Ott K. Wieder HA, et al. Recent Results Cancer Res. 2008;170:71-9. doi: 10.1007/978-3-540-31203-1_6. Recent Results Cancer Res. 2008. PMID: 18019618 Review. No abstract available.

5

Therapy Monitoring with Fluorine-18 FDG-PET and Fluorine-18 FDG-PET/CT.

Wieder HA, Herrmann K. Wieder HA, et al. PET Clin. 2008 Apr;3(2):217-26. doi: 10.1016/j.cpet.2008.08.009. Epub 2008 Dec 6. PET Clin. 2008. PMID: 27156465 Review.

6

PET and PET-CT in esophageal and gastric cancer.

Wieder HA, Krause BJ, Herrmann K. Wieder HA, et al. Methods Mol Biol. 2011;727:59-76. doi: 10.1007/978-1-61779-062-1_5. Methods Mol Biol. 2011. PMID: 21331929

7

18FDG-PET to assess recurrence and long term survival in patients with malignant melanoma.

Wieder HA, Tekin G, Rosenbaum-Krumme S, Klode J, Altenbernd J, Bockisch A, Nagarajah J. Wieder HA, et al. Nuklearmedizin. 2013;52(5):198-203. doi: 10.3413/Nukmed-0584-13-05. Epub 2013 Aug 23. Nuklearmedizin. 2013. PMID: 23969722

8

Predictive value of initial 18F-FLT uptake in patients with aggressive non-Hodgkin lymphoma receiving R-CHOP treatment.

Herrmann K, Buck AK, Schuster T, Junger A, Wieder HA, Graf N, Ringshausen I, Rudelius M, Wester HJ, Schwaiger M, Keller U, Dechow T. Herrmann K, et al. Among authors: wieder ha. J Nucl Med. 2011 May;52(5):690-6. doi: 10.2967/jnumed.110.084566. Epub 2011 Apr 15. J Nucl Med. 2011. PMID: 21498532 Free article. Clinical Trial.

9

Imaging of proliferation in hepatocellular carcinoma with the in vivo marker 18F-fluorothymidine.

Eckel F, Herrmann K, Schmidt S, Hillerer C, Wieder HA, Krause BJ, Schuster T, Langer R, Wester HJ, Schmid RM, Schwaiger M, Buck AK. Eckel F, et al. Among authors: wieder ha. J Nucl Med. 2009 Sep;50(9):1441-7. doi: 10.2967/jnumed.109.065896. Epub 2009 Aug 18. J Nucl Med. 2009. PMID: 19690030 Free article.

10

Early response assessment using 3'-deoxy-3'-[18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma.

Herrmann K, Wieder HA, Buck AK, Schöffel M, Krause BJ, Fend F, Schuster T, Meyer zum Büschenfelde C, Wester HJ, Duyster J, Peschel C, Schwaiger M, Dechow T. Herrmann K, et al. Among authors: wieder ha. Clin Cancer Res. 2007 Jun 15;13(12):3552-8. doi: 10.1158/1078-0432.CCR-06-3025. Clin Cancer Res. 2007. PMID: 17575218

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

20 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year